Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation

Luo, Fangyuan; Sun, Liping; Wang, Zhe; Zhang, Yuekun; Li, Jiaju; Chen, Yingwei; Dong, Jianzeng

doi:10.1007/s10557-022-07368-2

Cited by 11 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 A similar conclusion was also drawn in 2 other retrospective studies, as the use of SGLT2i among patients with AF and comorbid diabetes undergoing ablation was associated with lower incidence of AF recurrence comparing to those without SGLT2i. 15 , 16 Our results alone and the pooled results from our meta‐analysis were in line with conclusions from the aforementioned studies, showing the potential attenuating effect of SGLT2i on AF recurrence after CA. Further large RCTs are required to testify to the effect of SGLT2i on AF recurrence in patients with diabetes undergoing CA.…”

Section: Discussionsupporting

confidence: 89%

“…After removing duplicates, the titles, abstracts, and full‐text articles were screened for all potentially eligible studies for inclusion. A total of 4 studies 14 , 15 , 16 (including this study) met the inclusion criteria and were analyzed in our meta‐analysis (Figure 4 ). The risk of bias was rated as low by the Newcastle‐Ottawa Scale, and basic information and patients’ baseline are shown in Table S6 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis

Zhao,

Jiang,

et al. 2023

JAHA

Self Cite

View full text Add to dashboard Cite

Background The association between sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and atrial fibrillation (AF) recurrence after catheter ablation among patients with diabetes and AF remains unclear. Methods and Results Patients with AF undergoing initial catheter ablation with a history of diabetes from the China AF registry were included. Patients using SGLT2i were identified and matched by propensity score with non‐SGLT2i patients in a 1:3 ratio. The main outcome was AF recurrence during the 18‐month follow‐up. A total of 138 patients with diabetes with SGLT2i therapy and 387 without SGLT2i were analyzed. AF recurrence occurred in 37 patients (26.8%) in the SGLT2i group and 152 patients (39.3%) in the non‐SGLT2i group during a total of 593.3 person‐years follow‐up. The SGLT2i group was associated with lower AF recurrence compared with the non‐SGLT2i group (hazard ratio, 0.63 [95% CI, 0.44–0.90], P =0.007). A total of 4 studies were analyzed in our meta‐analysis demonstrating that SGLT2i was associated with lower AF recurrence after catheter ablation (odds ratio, 0.61 [95% CI, 0.54–0.69]; P <0.001, I 2 =0.0%). Conclusions Our prospective study coupled with a meta‐analysis demonstrated a lower risk of AF recurrence with the use of SGLT2i among patients with diabetes after AF ablation.

show abstract

Section: Discussionsupporting

confidence: 89%